Brexit: UK Gov’t Says Retaining The EMA Cannot Be A “Line In The Sand” Matter

The European Medicines Agency is important to the UK but the government cannot say it will be a non-negotiable point in future talks regarding the country’s departure from the EU.

“For me to say it is an absolute line in the sand that the EMA must stay in the UK would be a nonsense.” Those were the words of a junior health minister speaking during a debate by UK members of parliament on the future of the currently London-based European Medicines Agency after the UK leaves the EU.

Issues such as the location of the EMA “and all that goes with it” will, of course, be part of...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from United Kingdom

More from Europe

EMA Sets New Priorities As Number Of RWE Studies Climbs 48%

 

Real-world data studies conducted by the European Medicines Agency increased by 48% according to its latest report on the topic, prompting the agency to consider how it can better integrate this type of evidence into regulatory decision-making.

The Politics Of Divisionals: How European Patentees Are Still Gaming The System

 
• By 

At Medicines for Europe’s legal affairs conference last month, divisional patents were once again a major subject of discussion. Attendees heard fresh details of how patentee games are preventing generics from hitting the market and restricting wider access to major medicines.

Spain’s Medicines Shortages Plan Clears Administrative Hurdles For Essential Medicine Manufacturers

 

A new plan to tackle medicine shortages proposes to develop a set of incentives for companies to manufacture essential medicines in Spain.